PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

Sasikumar et al. describe the identification and characterization of CA-170, a small molecule inhibitor of PD-L1 and VISTA. They find that CA-170 activates T cells and exhibits anti-tumor efficacy in mouse models. This study highlights the potential of CA-170, which has advanced to human clinical tr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pottayil G. Sasikumar, Naremaddepalli S. Sudarshan, Srinivas Adurthi, Raghuveer K. Ramachandra, Dodderi S. Samiulla, Anirudha Lakshminarasimhan, Anuradha Ramanathan, Talapaneni Chandrasekhar, Amit A. Dhudashiya, Sumalatha R. Talapati, Nagesh Gowda, Sreenivasulareddy Palakolanu, Jiju Mani, Bandi Srinivasrao, David Joseph, Nigam Kumar, Rashmi Nair, Hanudatta S. Atreya, Nagaraj Gowda, Murali Ramachandra
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/0dc6fdd12b8e4be4a3c38267bc1cd96a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0dc6fdd12b8e4be4a3c38267bc1cd96a
record_format	dspace
spelling	oai:doaj.org-article:0dc6fdd12b8e4be4a3c38267bc1cd96a2021-12-02T15:02:51ZPD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy10.1038/s42003-021-02191-12399-3642https://doaj.org/article/0dc6fdd12b8e4be4a3c38267bc1cd96a2021-06-01T00:00:00Zhttps://doi.org/10.1038/s42003-021-02191-1https://doaj.org/toc/2399-3642Sasikumar et al. describe the identification and characterization of CA-170, a small molecule inhibitor of PD-L1 and VISTA. They find that CA-170 activates T cells and exhibits anti-tumor efficacy in mouse models. This study highlights the potential of CA-170, which has advanced to human clinical trials, as an anti-cancer drug.Pottayil G. SasikumarNaremaddepalli S. SudarshanSrinivas AdurthiRaghuveer K. RamachandraDodderi S. SamiullaAnirudha LakshminarasimhanAnuradha RamanathanTalapaneni ChandrasekharAmit A. DhudashiyaSumalatha R. TalapatiNagesh GowdaSreenivasulareddy PalakolanuJiju ManiBandi SrinivasraoDavid JosephNigam KumarRashmi NairHanudatta S. AtreyaNagaraj GowdaMurali RamachandraNature PortfolioarticleBiology (General)QH301-705.5ENCommunications Biology, Vol 4, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Biology (General) QH301-705.5
spellingShingle	Biology (General) QH301-705.5 Pottayil G. Sasikumar Naremaddepalli S. Sudarshan Srinivas Adurthi Raghuveer K. Ramachandra Dodderi S. Samiulla Anirudha Lakshminarasimhan Anuradha Ramanathan Talapaneni Chandrasekhar Amit A. Dhudashiya Sumalatha R. Talapati Nagesh Gowda Sreenivasulareddy Palakolanu Jiju Mani Bandi Srinivasrao David Joseph Nigam Kumar Rashmi Nair Hanudatta S. Atreya Nagaraj Gowda Murali Ramachandra PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
description	Sasikumar et al. describe the identification and characterization of CA-170, a small molecule inhibitor of PD-L1 and VISTA. They find that CA-170 activates T cells and exhibits anti-tumor efficacy in mouse models. This study highlights the potential of CA-170, which has advanced to human clinical trials, as an anti-cancer drug.
format	article
author	Pottayil G. Sasikumar Naremaddepalli S. Sudarshan Srinivas Adurthi Raghuveer K. Ramachandra Dodderi S. Samiulla Anirudha Lakshminarasimhan Anuradha Ramanathan Talapaneni Chandrasekhar Amit A. Dhudashiya Sumalatha R. Talapati Nagesh Gowda Sreenivasulareddy Palakolanu Jiju Mani Bandi Srinivasrao David Joseph Nigam Kumar Rashmi Nair Hanudatta S. Atreya Nagaraj Gowda Murali Ramachandra
author_facet	Pottayil G. Sasikumar Naremaddepalli S. Sudarshan Srinivas Adurthi Raghuveer K. Ramachandra Dodderi S. Samiulla Anirudha Lakshminarasimhan Anuradha Ramanathan Talapaneni Chandrasekhar Amit A. Dhudashiya Sumalatha R. Talapati Nagesh Gowda Sreenivasulareddy Palakolanu Jiju Mani Bandi Srinivasrao David Joseph Nigam Kumar Rashmi Nair Hanudatta S. Atreya Nagaraj Gowda Murali Ramachandra
author_sort	Pottayil G. Sasikumar
title	PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
title_short	PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
title_full	PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
title_fullStr	PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
title_full_unstemmed	PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
title_sort	pd-1 derived ca-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/0dc6fdd12b8e4be4a3c38267bc1cd96a
work_keys_str_mv	AT pottayilgsasikumar pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT naremaddepallissudarshan pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT srinivasadurthi pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT raghuveerkramachandra pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT dodderissamiulla pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT anirudhalakshminarasimhan pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT anuradharamanathan pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT talapanenichandrasekhar pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT amitadhudashiya pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT sumalathartalapati pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT nageshgowda pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT sreenivasulareddypalakolanu pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT jijumani pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT bandisrinivasrao pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT davidjoseph pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT nigamkumar pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT rashminair pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT hanudattasatreya pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT nagarajgowda pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy AT muraliramachandra pd1derivedca170isanoralimmunecheckpointinhibitorthatexhibitspreclinicalantitumorefficacy
_version_	1718389059752034304

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

Ejemplares similares